TNFRSF9 and melanoma: Different studies based on agent-based models [111] and delay differential equations (DDE) [114] have been conducted for exploring combined immunotherapy strategies (e.g., combining activated OT1 cytotoxic T lymphocytes (CTLs) and anti-CD137 monoclonal antibodies) for melanoma treatment in virtual mouse models [66,111].